Loading clinical trials...
Loading clinical trials...
Belimumab-Based Plasma Cell Targeted Therapy to Impact Transplant Eligibility
Conditions
Interventions
belimumab
Bortezomib
+2 more
Locations
2
United States
The Christ Hospital
Cincinnati, Ohio, United States
University of Cincinnati
Cincinnati, Ohio, United States
Start Date
June 1, 2015
Primary Completion Date
June 1, 2018
Completion Date
August 1, 2018
Last Updated
April 22, 2019
NCT03719339
NCT05756036
NCT06438107
NCT02377193
NCT04530630
NCT01239472
Lead Sponsor
E. Steve Woodle
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions